Erratum
n.b. The errors and associated corrections described in this document concerning the original manuscript were accountable to the production department handling this manuscript, and thus are no fault of the authors of this paper. Additionally, the online manuscript has now been updated with these corrections accordingly.
In the original publication of this article [1], Fig. 3 had [VALUE] (0.72, 2.23) where it should have said 1.27 (0.72, 2.23). This has now been updated in the original article.
Fig. 3.

Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI confidence interval, CV cardiovascular, DRV darunavir, HR hazard ratio, PI protease inhibitor
Footnotes
The online version of the original article can be found under doi:10.1186/s12879-016-1827-1.
References
- 1.Rosenblatt L, et al. Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study. BMC Infect Dis. 2016;16:492. doi: 10.1186/s12879-016-1827-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
